Asep Medical Holdings Inc. (SEPSF)

Asep Medical Holdings is a medical technology company that works on two sides of infection: identifying when sepsis is about to turn deadly, and developing drug candidates to fight it. The company’s main product is a blood test called SepsetER that tells doctors within an hour whether a patient’s body is heading toward severe sepsis — a condition responsible for roughly one death in five worldwide. On the drug side, Asep is developing peptide-based therapies designed to disrupt the sticky communities of bacteria called biofilms, which are notoriously hard to kill with conventional antibiotics.

What sepsis is and why speed matters

Sepsis starts when an infection — from surgery, a wound, appendicitis, pneumonia, or any number of sources — triggers a runaway inflammatory response in the body. The immune system overreacts, flooding the bloodstream with chemicals meant to fight the invader but ultimately damaging the patient’s own organs instead. Septic shock, the worst form, can kill in hours.

The problem is timing. When sepsis begins, you cannot tell by looking at a patient or glancing at basic vital signs whether they are about to plunge into severe disease or whether their immune system will contain the infection. Standard blood cultures take days to grow bacteria. Blood biomarkers like lactate or C-reactive protein are crude signals — they tell you inflammation is happening, not whether the patient will decompensate. So doctors play it safe: anyone who might have sepsis gets aggressive antibiotics and ICU care, even when many of them never would have gotten truly sick. The cost is enormous — sepsis kills hundreds of thousands in the US alone each year and is one of the leading drivers of healthcare spending. The waste is real too: many patients treated intensively for potential sepsis never needed that level of care.

SepsetER: finding the signal in the noise

Asep’s core technology is a gene expression signature — a pattern of genes that switch on or off in the blood when sepsis is about to turn severe. The company’s founders, led by CEO and scientist Robert Hancock, spent years studying which genetic markers predict progression to sepsis in specific populations, including children with appendicitis. The signature is validated in peer-reviewed research, including a 2024 study published in JAMA Pediatrics showing the test can distinguish between simple appendicitis and the dangerous perforated kind.

SepsetER works from a simple blood draw. Send the sample to a lab, and within about an hour the test returns a risk score: the genes do or don’t light up in a way that suggests the patient is on a path toward critical illness. That signal lets clinicians decide whether to escalate care or step back. In appendicitis, for instance, a patient with a low gene expression score likely has a simple inflammation and might safely avoid surgery. A high score suggests perforation, where surgery is urgent.

The company has also featured this work in partnerships with television and other media. In 2024, Asep’s technology was highlighted in a national documentary series called Empowered, broadcast on public television and hosted by Meg Ryan, giving the diagnostic approach broader public recognition.

The peptide angle: fighting biofilms

Alongside the diagnostic business, Asep is developing therapeutic peptides — short chains of amino acids designed to mimic the body’s own natural defenses. Many bacterial infections are protected by biofilms, a slimy matrix where bacteria hide and become nearly impervious to antibiotics. Asep’s peptides are engineered to punch through that shield and either kill the bacteria directly or modulate the immune system to help the body fight back more effectively.

The applications span several categories: antimicrobial peptides for direct bacterial killing, coatings for medical devices to prevent infection-prone biofilm growth, anti-inflammatory peptides to temper the runaway immune response in sepsis itself, and vaccine adjuvants to prime immune protection. None of these are small markets. Hospital-acquired infections, device-related infections, and complications from surgery all create demand for better tools.

The business model and revenue

Asep is building a two-part commercial engine. The diagnostic test generates revenue through lab fees — each SepsetER test processed generates billable revenue, similar to any clinical blood test. The reimbursement model depends on payers accepting the test’s clinical utility, a process that is ongoing. If the test’s predictive power is accepted by hospital systems and insurance companies, it could be run thousands of times per day across US hospitals alone.

The therapeutic peptides represent a longer development arc. Drug development takes time, regulatory approval takes more time, and market launch takes even more. But if any of these candidates succeed, the therapeutic business could eventually dwarf the diagnostic one, because drugs often command much higher prices and faster revenue growth than tests.

The regulatory path and the risks

Asep’s diagnostic test is not a simple COVID-style antigen swab that barely requires FDA oversight. Gene expression tests fall into a complex regulatory zone: they are often validated as lab-developed tests, which the FDA traditionally leaves to state regulation and clinical laboratory standards, but the agency is increasingly asserting authority over high-risk diagnostic tests. The company will need to maintain rigorous validation, publish results openly, and work with major hospital systems to build trust in the test’s clinical value.

The therapeutic peptides face the full gauntlet of drug development: animal testing, human trials, regulatory review, manufacturing scale-up. Many promising peptide candidates fail in human trials. The company’s technology is grounded in published science and appears serious, but the path from bench to marketed drug is long and expensive.

Asep is an early-stage biotech company competing in markets dominated by large pharmaceutical and diagnostics firms. Its advantages lie in the specificity of its founder-led science and the genuine clinical problem it is trying to solve. Its risks are the normal ones: scientific setback, slower-than-hoped adoption, competition from established players, and the simple reality that most early biotech companies burn cash faster than they generate revenue.

How to research the company

Start with Asep’s SEC filings under CIK 0001969766 if and when the company becomes SEC-reporting. For the latest news, watch for press releases on its website and news about clinical partnerships. The published research on the gene expression signature in sepsis provides the scientific foundation and is worth reading to understand what the company is actually measuring. Any investigation should focus on whether hospital systems are actually adopting the diagnostic test, whether reimbursement is being granted, and whether any of the peptide candidates are advancing toward human trials.